Walvax沃森生物

CN
EN

Help Everyone Live a Healthy Life

Walvax publishes safety and non-inferior immunogenicity results of its MPV ACYW135 compared with Menactra® in Human Vaccines & Immunotherapeutics

 

ㅤㅤㅤ

ㅤㅤㅤ

Walvax publishes data on safety, immunogenicity and immune persistence from the Phase 2 trial of its HPV2 vaccine Walrinvax™ in Human Vaccines & Immunotherapeutics

ㅤㅤㅤ

ㅤㅤㅤ

ㅤㅤㅤ

ㅤㅤㅤ

Walvax Publishes Immunogenicity and Safety Data

from Phase 3 Clinical Study of PCV13

in Frontiers in Microbiology

 

ㅤㅤㅤ

ㅤㅤㅤ

ㅤㅤㅤ

Advanced, Modular and Digital mRNA Workshop

Investors

Walvax aims to become a high-quality, cost-effective and sustainable global vaccine producer. 

R&D

We have abundant blockbuster pipelines in clinical stage, and keep investing a significant amount of revenue into R&D.  

Products

We have successfully developed and licensed 9 vaccines and protected hundreds of millions of people from diseases. 

About Walvax

Founded in 2001, Walvax is mainly engaged in research and development, manufacturing and distribution of safe and efficacious vaccines. With the purpose of “Help everyone live a healthy life”, Walvax aims to be a leader in public health, sustainably providing high-quality and innovative products to protect against the world’s deadliest diseases.

Learn More
706.4
USD706.4 million revenue in 2022
46.9%
46.9% increase in revenue since 2021
TOP 8
Top 8 manufacturers by value in 2021 (excluding COVID-19 vaccines) ——WHO's Global Vaccine Market Report 2022
7
7 new vaccines under development
74
74 authorized invention patents at home and abroad
10+
10+ patents application in progress
220+
220+ cities covered in China
18
Products exported to 18 countries
23
23 countries registration in progress
80+
Engaged 80+ partners in 5 continents

Join Us

You’ll partner with colleagues of diverse backgrounds and abilities. 

Responsibility

We are focused on the areas of greatest need.